PASG · Passage Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $23.28M | $40.18M | $61.42M | $86.05M | $117.67M | $81.79M |
| SG&A | $19.88M | $24.99M | $41.58M | $49.34M | $60.06M | $30.11M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $728.0K | $3.08M | $3.72M | $3.68M | $1.54M | $800.0K |
| Operating Income | ($49.30M) | ($70.40M) | ($108.39M) | ($138.39M) | ($185.73M) | ($112.90M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - |
| Net Income | ($45.52M) | ($64.77M) | ($102.06M) | ($136.13M) | ($185.39M) | ($112.23M) |
| EPS - Basic | ($14.35) | ($21.40) | ($37.20) | ($50.00) | ($58.20) | - |
| EPS - Diluted | ($14.35) | ($21.40) | ($37.20) | ($50.00) | ($58.20) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $46.30M | $37.57M | $21.71M | $34.60M | $128.97M | $135.00M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.11M | $742.0K | $1.30M | $4.07M | $9.45M | $5.26M |
| Current Assets | $47.76M | $78.81M | $117.96M | $197.04M | $325.07M | $317.18M |
| Total Assets | $62.28M | $102.41M | $150.54M | $243.55M | $355.08M | $328.01M |
| Current Liabilities | $23.08M | $19.36M | $16.34M | $18.35M | $29.50M | $21.18M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $43.53M | $41.15M | $39.26M | $42.18M | $36.42M | $23.29M |
| Stockholders' Equity | $18.75M | $61.26M | $111.28M | $201.37M | $318.66M | $304.71M |
| Retained Earnings | ($704.76M) | ($659.24M) | ($594.47M) | ($492.41M) | ($356.28M) | ($170.90M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($31.51M) | ($47.96M) | ($78.26M) | ($118.21M) | ($126.88M) | ($80.52M) |
| Investing Cash Flow | $40.22M | $54.95M | $65.24M | $25.20M | ($45.81M) | ($172.11M) |
| Financing Cash Flow | $23.0K | $8.87M | $135.0K | ($1.35M) | $166.66M | $228.75M |
| CapEx | $34.0K | - | - | - | - | - |
| Free Cash Flow | ($31.54M) | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.69 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -73.1% | -63.2% | -67.8% | -55.9% | -52.2% | -34.2% |
| Return on equity | -242.7% | -105.7% | -91.7% | -67.6% | -58.2% | -36.8% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.07 | 4.07 | 7.22 | 10.74 | 11.02 | 14.98 |
| Quick ratio | 2.07 | 4.07 | 7.22 | 10.74 | 11.02 | 14.98 |
| Cash ratio | 2.01 | 1.94 | 1.33 | 1.89 | 4.37 | 6.38 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 3.32 | 1.67 | 1.35 | 1.21 | 1.11 | 1.08 |
| Liabilities / Assets | 0.70 | 0.40 | 0.26 | 0.17 | 0.10 | 0.07 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 2.0x | 11.2x | 9.9x | 7.5x | 15.4x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 30.0% | 35.0% | 21.7% | 25.5% | -64.5% | - |
| Net income growth (YoY) | 29.7% | 36.5% | 25.0% | 26.6% | -65.2% | - |
| EPS growth (YoY) | 32.9% | 42.5% | 25.6% | 14.1% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -69.4% | -45.0% | -44.7% | -36.8% | 4.6% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Passage BIO against the 5 most active filers in the same SIC group.